A Registry Study of Biomarkers in Ischemic Heart Disease ( BIOMS-IHD )

Recruiting

• Conditions: Cardiovascular Diseases

• Registration Number: NCT05965882
• Lead Sponsor: Beijing Institute of Heart, Lung and Blood Vessel Diseases

Brief Summary

The registry study aims to discover biomarkers for accurate classification and risk assessment of ischemic heart disease.

Detailed Description

The purpose of this study is to discover biomarkers for early identification, diagnosis, molecular classification, and intervention based on the mechanism of ischemic heart disease（IHD）. Using mass spectrometry-based metabolomics and multimodal imaging technology, the study aims to further construct a new system for early risk stratification of IHD based on abnormal metabolites.

Study Timeline

• Study Start: 2016-06
• Study First Submitted: 2023-07-20
• Study First Submitted QC: 2023-07-20
• Study First Posted: 2023-07-28
• Status Verified: 2024-01
• Last Update Submitted: 2024-01-25
• Last Update Posted: 2024-01-29
• Primary Completion: 2024-06
• Study Completion: 2024-06

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 5000

Inclusion Criteria

Not provided

Exclusion Criteria

• Current known inability to follow instructions or comply with follow-up procedures.
• Eligible patients without informed consent form

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Number of hospitalizations for acute heart failure (HF)	These data is collected during follow-up visit at 3/6/12/24/36/48 months after discharge	Unplanned emergency visits or hospitalizations leading to HF deterioration were defined as hospitalizations for HF

Secondary Outcome Measures

Name	Time	Method
Number of major adverse cardiovascular events (MACE)	These data is collected during follow-up visit at 3/6/12/24/36/48 months after discharge	Major adverse cardiovascular events (MACE) in overall population, defined as composite of all-cause death, Heart Failure hospitalization, recurrent myocardial infarction, stroke or ischemia-driven revascularization.

Trial Locations

Locations (1)

Beijing Anzhen Hospital; 🇨🇳 Beijing, Beijing, China